Insider Selling: Alignment Healthcare (NASDAQ:ALHC) CEO Sells $853,287.55 in Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) CEO John Kao sold 48,899 shares of the firm’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $17.45, for a total value of $853,287.55. Following the transaction, the chief executive officer owned 1,519,480 shares in the company, valued at approximately $26,514,926. This trade represents a 3.12% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Alignment Healthcare Price Performance

Alignment Healthcare stock opened at $16.99 on Monday. The company has a current ratio of 1.71, a quick ratio of 1.71 and a debt-to-equity ratio of 1.80. The firm has a market capitalization of $3.47 billion, a P/E ratio of -1,697.30, a PEG ratio of 2.49 and a beta of 1.19. The business has a 50-day moving average of $20.76 and a 200-day moving average of $18.77. Alignment Healthcare, Inc. has a 1 year low of $11.63 and a 1 year high of $23.87.

Alignment Healthcare (NASDAQ:ALHC) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.10. Alignment Healthcare had a negative net margin of 0.02% and a negative return on equity of 0.49%. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same period last year, the company posted ($0.16) EPS. Alignment Healthcare’s revenue for the quarter was up 44.4% on a year-over-year basis. On average, equities analysts anticipate that Alignment Healthcare, Inc. will post -0.69 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. JPMorgan Chase & Co. lifted their price target on shares of Alignment Healthcare from $23.00 to $26.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. KeyCorp restated an “overweight” rating and issued a $28.00 price objective on shares of Alignment Healthcare in a research report on Thursday, January 22nd. Piper Sandler raised their price objective on Alignment Healthcare from $20.00 to $30.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 6th. TD Cowen lifted their target price on Alignment Healthcare from $18.50 to $25.00 and gave the stock a “buy” rating in a report on Friday, January 16th. Finally, Wall Street Zen cut Alignment Healthcare from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $24.56.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Royal Bank of Canada increased its position in shares of Alignment Healthcare by 92.6% during the first quarter. Royal Bank of Canada now owns 92,379 shares of the company’s stock worth $1,720,000 after acquiring an additional 44,413 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Alignment Healthcare by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,557 shares of the company’s stock worth $1,109,000 after acquiring an additional 2,594 shares during the period. Goldman Sachs Group Inc. lifted its position in Alignment Healthcare by 79.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 972,715 shares of the company’s stock valued at $18,112,000 after acquiring an additional 429,703 shares in the last quarter. Woodline Partners LP acquired a new position in Alignment Healthcare in the 1st quarter worth $2,142,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Alignment Healthcare by 16.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 307,655 shares of the company’s stock worth $5,729,000 after purchasing an additional 44,452 shares during the period. Institutional investors own 86.19% of the company’s stock.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.